InMed (OTCQB: IMLFF) CEO Discusses R&D Pipeline on BNN
January 10th, 2017
News, Top News
InMed Pharmaceuticals Inc. (OTCQB: IMLFF) (CSE: IN), a pre-clinical biopharmaceutical firm developing novel cannabinoid therapies, was recently featured on Canada’s Business News Network (BNN). In the interview, CEO Eric A. Adams discusses the cannabis plant’s enormous potential for new therapies in the pharmaceutical industry and highlights the company’s R&D pipeline targeting serious medical conditions like Epidermolysis Bullosa (EB) and Glaucoma.
Watch the entire BNN segment here:
In this article, we will look at the company’s approach within the industry and why investors may want to consider the stock right now.
Beyond THC and CBD
InMed Pharma CEO Eric A. Adams noted that there are more than 90 cannabinoids, or individual drugs, present in the marijuana plant during his interview with BNN. Most people have heard of THC and CBD, both of which have significant effects in the human body. And, since THC and CBD account for about 80-90% of cannabinoid drug quantity in the plant and are therefore economically viable to grow-harvest-extract-purify, most companies have focused on developing these two compounds for clinical purposes. The other ‘minor’ cannabinoids tend to occur in very low concentrations in the marijuana plant and are therefore costly and difficult to extract.
InMed is developing a high-yield and low-cost process to biosynthesize cannabinoids utilizing a process that is similar to how insulin is currently mass-produced. The process begins by isolating the genes in the cannabis plant that are responsible for producing specific cannabinoids. Next, these genes are injected into bacteria that act as a factory for producing the cannabinoid at scale. This process enables the company to cost-effectively produce any cannabinoid that may be beneficial in treating human disease. This is truly a 21st century approach to cannabinoid therapeutics.
Expanding R&D Pipeline
InMed Pharma is developing two therapeutics, leveraging combinations of cannabinoids to treat Epidermolysis Bullosa (EB) and Glaucoma. Based on the information provided by the company’s bioinformatics assessment tool, leading to expedited validation in early pre-clinical models, the InMed team chose to focus on EB given that it’s an orphan indication with a significant unmet medical need, tremendously impacting quality of life, and there are no existing treatments or cures. The company hopes to develop a therapeutic that will both treat the devastating symptoms of the disease as well as potentially have a significant impact on the underlying disease itself.
Currently, the company is focused on finalizing the transdermal formulation of the EB therapy, as well as completing some pre-clinical toxicology work on the final product. The team plans to begin clinical trials in about a year and launch the drug in about four years – a shorter than usual timeframe due to the orphan drug status and a potential to ‘fast-track’ the approval process given the therapeutic potential in this horrible disease. In fact, the company estimates that only 200-300 patients will be needed to complete the clinical trials from start to finish…a highly manageable clinical path for a small biotech company and the potential to unlock significant value for shareholders.
InMed Pharmaceuticals (OTCQB: IMLFF) (CSE: IN) has spent the past year validating its drug candidate selection in pre-clinical models, using data to secure patents, and further developing its disruptive technology. In 2017, the company plans to continue the path that it forged in 2016 by furthering the development its two leading products in EB and glaucoma, researching the fundamentals of cannabinoids and their impacts in other diseases with high unmet medical needs, expanding the management team beyond the existing core of biopharmaceutical veterans, and collaborating with seasoned biopharmaceutical investors committed to realizing its potential.
For more information, visit the company’s website at www.inmedpharma.com.
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.